Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.75 -6.2%	$1.95	$1.54 ▼ $5.50	$64.44M	1.19	879,638 shs	968,696 shs
CORT Corcept Therapeutics	$85.90 -6.5%	$73.41	$28.66 ▼ $95.11	$9.86B	0.47	945,353 shs	1.33 million shs
RPRX Royalty Pharma	$56.45 +0.0%	$54.48	$34.08 ▼ $58.84	$32.49B	0.43	3.25 million shs	2.22 million shs
ZTS Zoetis	$75.46 -0.1%	$79.17	$71.47 ▼ $160.48	$31.68B	0.75	6.34 million shs	6.09 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-6.33%	-11.65%	-3.32%	+1.45%	-35.85%
CORT Corcept Therapeutics	-6.51%	-6.23%	+3.61%	+96.66%	+19.50%
RPRX Royalty Pharma	+0.04%	-0.83%	+2.88%	+15.63%	+57.51%
ZTS Zoetis	-0.04%	+0.08%	-5.10%	-37.70%	-51.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$1.75 -6.2%	$1.95	$1.54 ▼ $5.50	$64.44M	1.19	879,638 shs	968,696 shs
CORT Corcept Therapeutics	$85.90 -6.5%	$73.41	$28.66 ▼ $95.11	$9.86B	0.47	945,353 shs	1.33 million shs
RPRX Royalty Pharma	$56.45 +0.0%	$54.48	$34.08 ▼ $58.84	$32.49B	0.43	3.25 million shs	2.22 million shs
ZTS Zoetis	$75.46 -0.1%	$79.17	$71.47 ▼ $160.48	$31.68B	0.75	6.34 million shs	6.09 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	-6.33%	-11.65%	-3.32%	+1.45%	-35.85%
CORT Corcept Therapeutics	-6.51%	-6.23%	+3.61%	+96.66%	+19.50%
RPRX Royalty Pharma	+0.04%	-0.83%	+2.88%	+15.63%	+57.51%
ZTS Zoetis	-0.04%	+0.08%	-5.10%	-37.70%	-51.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	2.60	Moderate Buy	$11.67	568.58% Upside
CORT Corcept Therapeutics	2.75	Moderate Buy	$88.83	3.41% Upside
RPRX Royalty Pharma	3.00	Buy	$56.57	0.22% Upside
ZTS Zoetis	2.41	Hold	$123.46	63.62% Upside

Current Analyst Ratings Breakdown

Latest CORT, ANVS, RPRX, and ZTS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/13/2026	RPRX Royalty Pharma	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $65.00
7/9/2026	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
7/7/2026	ANVS Annovis Bio	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/6/2026	ANVS Annovis Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/6/2026	ZTS Zoetis	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$140.00 ➝ $95.00
7/1/2026	ZTS Zoetis	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$136.00 ➝ $85.00
6/30/2026	ZTS Zoetis	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$150.00 ➝ $104.00
6/26/2026	ZTS Zoetis	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$95.00 ➝ $85.00
6/24/2026	CORT Corcept Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C-)
6/15/2026	CORT Corcept Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 7/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.64 per share	N/A
CORT Corcept Therapeutics	$761.41M	12.11	$0.84 per share	101.78	$6.16 per share	13.94
RPRX Royalty Pharma	$2.38B	13.67	$4.78 per share	11.81	$16.83 per share	3.35
ZTS Zoetis	$9.47B	3.34	$7.55 per share	9.99	$7.56 per share	9.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$28.85M	-$1.71	N/A	N/A	N/A	N/A	-318.08%	-215.47%	8/11/2026 (Estimated)
CORT Corcept Therapeutics	$99.65M	$0.35	245.44	37.84	N/A	6.14%	7.40%	5.76%	7/30/2026 (Estimated)
RPRX Royalty Pharma	$770.95M	$1.47	38.40	10.23	1.55	33.88%	29.25%	14.71%	8/5/2026 (Estimated)
ZTS Zoetis	$2.67B	$6.03	12.51	10.25	1.18	27.80%	66.85%	18.79%	8/6/2026 (Estimated)

Latest CORT, ANVS, RPRX, and ZTS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ANVS Annovis Bio	-$0.44	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	ZTS Zoetis	$1.85	N/A	N/A	N/A	$2.51 billion	N/A
8/5/2026	Q2 2026	RPRX Royalty Pharma	$1.27	N/A	N/A	N/A	$789.52 million	N/A
7/30/2026	Q2 2026	CORT Corcept Therapeutics	$0.0123	N/A	N/A	N/A	$219.13 million	N/A
5/15/2026	Q1 2026	ANVS Annovis Bio	-$0.3950	-$0.63	-$0.2350	-$0.63	N/A	N/A
5/7/2026	Q1 2026	ZTS Zoetis	$1.60	$1.53	-$0.07	$1.42	$2.30 billion	$2.26 billion
5/6/2026	Q1 2026	RPRX Royalty Pharma	$1.22	$1.30	+$0.08	$0.67	$881.69 million	$630.58 million
4/30/2026	Q1 2026	CORT Corcept Therapeutics	-$0.1085	-$0.30	-$0.1915	-$0.30	$185.83 million	$164.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
CORT Corcept Therapeutics	N/A	N/A	N/A	N/A	N/A
RPRX Royalty Pharma	$0.94	1.67%	+24.01%	63.95%	5 Years
ZTS Zoetis	$2.12	2.81%	+20.11%	35.16%	14 Years

Latest CORT, ANVS, RPRX, and ZTS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2026	ZTS Zoetis	quarterly	$0.53	2.66%	7/20/2026	7/20/2026	9/1/2026
4/17/2026	RPRX Royalty Pharma	quarterly	$0.2350	1.78%	5/15/2026	5/15/2026	6/10/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	1.27	1.27
CORT Corcept Therapeutics	N/A	2.86	2.77
RPRX Royalty Pharma	0.86	2.66	2.66
ZTS Zoetis	2.80	3.15	1.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
CORT Corcept Therapeutics	93.61%
RPRX Royalty Pharma	54.35%
ZTS Zoetis	92.80%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
CORT Corcept Therapeutics	20.70%
RPRX Royalty Pharma	18.84%
ZTS Zoetis	0.22%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	34.65 million	27.44 million	Optionable
CORT Corcept Therapeutics	300	107.35 million	85.13 million	Optionable
RPRX Royalty Pharma	80	575.83 million	467.35 million	Optionable
ZTS Zoetis	14,500	419.23 million	418.31 million	Optionable

CORT, ANVS, RPRX, and ZTS Headlines

Recent News About These Companies

Zoetis: Buy When There Is Blood In The Streets

2 hours ago | seekingalpha.com

Zoetis Inc. $ZTS Shares Bought by Schwartz Investment Counsel Inc.

3 hours ago | marketbeat.com

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

July 13 at 12:00 PM | globenewswire.com

ZTS Shareholder Alert: July 27, 2026 Lead Plaintiff Deadline in Zoetis Inc. Securities Class Action - Contact Levi & Korsinsky

July 13 at 10:00 AM | globenewswire.com

Midwest Trust Co Acquires 24,378 Shares of Zoetis Inc. $ZTS

July 13 at 5:27 AM | marketbeat.com

Zoetis Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ZTS

July 13 at 4:22 AM | prnewswire.com

ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 13 at 4:10 AM | prnewswire.com

ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

July 12 at 4:07 PM | newsfilecorp.comN

LGT Fund Management Co Ltd. Buys 31,000 Shares of Zoetis Inc. $ZTS

July 12 at 1:52 PM | marketbeat.com

Pittenger & Anderson Inc. Purchases 16,975 Shares of Zoetis Inc. $ZTS

July 12 at 1:28 PM | marketbeat.com

UNIVEST FINANCIAL Corp Has $6.21 Million Position in Zoetis Inc. $ZTS

July 12 at 1:20 PM | marketbeat.com

Bronstein, Gewirtz & Grossman LLC Urges Zoetis Inc. Investors to Act: Class Action Filed Alleging Investor Harm

July 12 at 12:00 PM | newsfilecorp.comN

Carnegie Investment Counsel Boosts Stock Holdings in Zoetis Inc. $ZTS

July 12 at 11:59 AM | marketbeat.com

ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

July 11 at 11:31 AM | markets.businessinsider.com

ZOETIS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ZTS

July 11 at 10:16 AM | newsfilecorp.comN

Sumitomo Mitsui Trust Group Inc. Has $113.93 Million Stake in Zoetis Inc. $ZTS

July 11 at 10:15 AM | marketbeat.com

Zoetis Inc. $ZTS Position Reduced by Integrated Advisors Network LLC

July 11 at 10:07 AM | marketbeat.com

Zoetis Inc. $ZTS Holdings Cut by Candriam S.C.A.

July 11 at 9:19 AM | marketbeat.com

Zoetis Deadline: ZTS Investors with Losses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit

July 10, 2026 | prnewswire.com

ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS

July 10, 2026 | globenewswire.com

Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

July 10, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT, ANVS, RPRX, and ZTS Company Descriptions

Annovis Bio NYSE:ANVS

$1.74 -0.12 (-6.18%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$1.74 -0.01 (-0.40%)

As of 08:42 AM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Corcept Therapeutics NASDAQ:CORT

$85.90 -5.98 (-6.51%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$86.25 +0.35 (+0.41%)

As of 08:49 AM Eastern

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Royalty Pharma NASDAQ:RPRX

$56.45 +0.02 (+0.04%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$56.70 +0.25 (+0.44%)

As of 08:48 AM Eastern

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Zoetis NYSE:ZTS

$75.46 -0.10 (-0.14%)

Closing price 07/13/2026 03:59 PM Eastern

Extended Trading

$75.53 +0.07 (+0.10%)

As of 08:44 AM Eastern

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CORT, ANVS, RPRX, and ZTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CORT, ANVS, RPRX, and ZTS Earnings

Compare Dividends

Latest CORT, ANVS, RPRX, and ZTS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CORT, ANVS, RPRX, and ZTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT, ANVS, RPRX, and ZTS Company Descriptions

Annovis Bio NYSE:ANVS

Corcept Therapeutics NASDAQ:CORT

Royalty Pharma NASDAQ:RPRX

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CORT, ANVS, RPRX, and ZTS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CORT, ANVS, RPRX, and ZTS Earnings

Compare Dividends

Latest CORT, ANVS, RPRX, and ZTS Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CORT, ANVS, RPRX, and ZTS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT, ANVS, RPRX, and ZTS Company Descriptions

Annovis Bio NYSE:ANVS

Corcept Therapeutics NASDAQ:CORT

Royalty Pharma NASDAQ:RPRX

Zoetis NYSE:ZTS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools